Medical Crossfire: How Do Recent Pathophysiological Findings in Pustular Psoriasis Have the Potential to Shape a New Treatment Paradigm?

Released On
July 28, 2020

Expires On
July 28, 2021

Media Type
Internet

Completion Time
90 minutes

Specialty
Allergy & Immunology, Dermatology

Topic(s)
Psoriasis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported an educational grant from Boehringer Ingelheim Pharmaceuticals Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

These activities are intended for attendees of the 2020 AAD Annual Meeting, including dermatologists, NPs, and PAs involved in the care and treatment of patients with pustular psoriasis.

Program Overview

The Medical Crossfire®, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirited discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the types and features of pustular psoriasis with a focus on the pathophysiological findings that have led to emerging treatments for the management of this devastating skin condition. This engaging discussion will help place new developments into clinical context for clinicians to optimize care of patients with pustular psoriasis.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Identify different types of pustular psoriasis based on symptom recognition, location, and accurate assessment of disease severity
  • Discuss recent pathophysiological findings in pustular psoriasis to differentiate from plaque psoriasis
  • Demonstrate increased knowledge of clinical data on emerging biologic therapies targeting the inflammatory pathway for treatment of pustular psoriasis

Faculty

Alan Menter, MD

CHAIR
Owner/Investigator
Texas Dermatology Associates, Menter Dermatology Research Institute / Menter Cosmetic Institute
Director, Dermatology Residency Program
Baylor University Medical Center
Dallas, TX

Lakshi Aldredge, MSN, ANP-BC, DCNP

Adult Nurse Practitioner
VA Portland Healthcare System
Portland, OR

Mark Lebwohl, MD

Waldman Chair of Dermatology
Professor and System Chair, Dermatology
Icahn School of Medicine
Mount Sinai
New York, NY

Abby S. Van Voorhees, MD

Professor and Chair, Dermatology
Eastern Virginia Medical School
Norfolk, VA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

Alan Menter, MD has no relevant financial relationships with commercial interests.

Lakshi Aldredge, MSN, ANP-BC, DCNP

  • Consultant: AbbVie, Sun Pharma, Lilly, Sanofi Genzyme, Regeneron
  • Speaker’s Bureau: AbbVie, Sun Pharma, Lilly, Sanofi Genzyme, Regeneron

Mark Lebwohl, MD

  • Grant/Research: : Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Leo Pharmaceuticals, Orth Dematologics, Pfizer, UCB, Inc.
  • Consultant: Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD Skincare, Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Theravance, and Verrica.

Abby S. Van Voorhees, MD

  • Grant/Research: Abbvie, Celgene, Lilly
  • Consultant: Dermtech, WebMD, Celgene, UCB, Novartis, Lilly, AbbVie

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/ Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.